comparemela.com

Latest Breaking News On - Bon secours cancer institute - Page 2 : comparemela.com

How Bon Secours hospital chain used a poor Virginia neighborhood to turn huge profits

Richmond Community consists of little more than a strapped emergency room and a psychiatric ward. Yet the hollowed-out hospital owned by Bon Secours Mercy Health has the highest profit margins of any hospital in Virginia.

How a Hospital Chain Used a Poor Neighborhood to Turn Huge Profits

Agendia, Inc : Data Presented at the Miami Breast Cancer Conference Show MammaPrint and BluePrint Accurately Predict Pathologic Complete Response Rate Regardless of Age

(1) Results support use of Agendia s genomic tests to better tailor pre-operative treatment and timing for surgery Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint and BluePrint , and underpin both assays pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38 th Annual Miami Breast Cancer Conference. The poster, entitled Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients, outlines the first age-based analyses of MammaPrint and BluePrint assays in the pre-operative setting. As expected, the data show that pCR rates varied according to molecular subtype, with MammaPrint and BluePrint accurately predicting pCR in patients of all subtypes, regard

Agendia, Inc : Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint

Agendia, Inc.: Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity within all clinical subtypes of breast cancer Agendia, Inc., a world leader in precision oncology for breast cancer, announced new 5-year data from the NBRST trial that will be presented in a poster spotlight discussion Thursday, December 10, 2020 from 3:30pm-4:45pm CST at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). The poster, entitled

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.